Atresia, a degenerative process through which many follicles are removed from the growing pool, involves apoptotic changes in the follicular granulosa cells. To identify histochemical markers of early stages of atresia, an in-vivo rat model was used which allowed the study of atresia of pre-ovulatory follicles in a synchronized and chronological order. By blocking the pre-ovulatory luteinizing ...

The objective of this study was to examine the degradation of short peptides corresponding to modified fragments of human growth hormone-releasing hormone by trypsin. Six analogues of pentapeptide 9-13 of human growth hormone-releasing hormone containing homoarginine, ornithine, glutamic acid, glycine, leucine or phenylalanine residue in position 11, two analogues of hexapeptide 8-13 of human g...

BACKGROUND Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications. OBJECTIVE/METHOD Here we give an overview of the most r...

introduction: numerous studies have demonstrated that kisspeptin, a peptide from the kiss1 gene, plays an important role in regulating the secretion of gonadotropin releasing hormone (gnrh). also, there is some evidence suggesting that kisspeptin can interact with other neuropeptides for the control of the reproductive axis. in the present study, we have investigated the effect of central admin...

OBJECTIVE We devised a novel strategy, a GnRH antagonist protocol with a GnRH agonist trigger followed by frozen-thawed blastocyst transfers with long zona dissection (LZD). The purpose of this study was to investigate the clinical outcomes of this new strategy according to age. METHODS Ninety women aged less than 35 (group A) and 32 women aged 35 to 39 (group B) underwent the GnRH antagonist...

BACKGROUND Given the controversies regarding the effectiveness of gonadotropin-releasing hormone (GnRH) antagonists in prevention of ovarian hyper stimulation syndrome stimulation, this study was designed to compare GnRH agonist protocol with GnRH antagonist protocol in patients who were candidate for assisted reproductive techniques (ARTs). MATERIALS AND METHODS This investigation was perfor...

The present study was aimed to examine the possible functional relationship between melatonin and hypothalamic transmitters, endogenous opioids and excitatory amino acids in controlling gonadotropin secretion in ovariectomized estrogen-primed rats. An intravenous injection of naloxone (mu opioid receptor antagonist), N-methyl-D-aspartate (NMDA; NMDA receptor agonist) or luteinizing hormone-rele...

RANKL: Receptor activator of nuclear factorkappa B ligand; PTHrP: Parathyroid Hormone Related Peptide; ACTH: Adrenocorticotropic Hormone; POMC: Pro-Opiomelanocortin; PNES: Paraneoplastic Endocrine Syndrome; OPG: Osteoprotegrin; CS: Cushing’s Syndrome; CLIP: Corticotrophin-Like Intermediate Lobe Peptide; MSH: α-Melanocyte Stimulating Hormone; CLIP: Corticotrophin-Like Intermediate Lobe Peptide; ...

Gonadotropin-releasing hormone (GnRH) receptor antagonists have potential in treating numerous hormone-dependent pathologies including cancers of the prostate, breast, and ovary, endometriosis, and fertility disorders. An unmet clinical need exists for an orally available GnRH receptor antagonist. Guided by structure-activity relationships, ligand-based targeted library designs, and biomarker m...

Background: Androgen deprivation therapy (ADT) by surgical or medical castration is recommended for advanced or metastatic prostate cancer. Recent literature suggests that medical castration by luteinizing hormone receptor hormone (LHRH) antagonists might have advantages over treatment with LHRH agonists in patients with metastatic prostate cancer when prostate specific antigen (PSA) progressio...